ETCTN Trials by Disease/Treatment Area: Genitourinary Cancer

- **Genitourinary cancer (various)**
  - Genitourinary cancer (various)
  - Urothelial cancer
  - Urothelial cancer with DNA-repair defects

- **Urothelial cancer**
  - Genitourinary cancer (various)
  - Urothelial cancer
  - Urothelial cancer with DNA-repair defects

- **Prostate cancer**
  - Castration-resistant prostate cancer

- **Renal cell carcinoma**
  - Progressive renal cell carcinoma

**Abbreviations:**
- **CaboNivoIpi:** A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
- **CaboNivo:** A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Entinostat in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
- **CaboNivoIpi:** A Pilot Study of Pazopanib and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: October 19, 2020